GlaxoSmithKline’s asthma drug ‘not cost effective’ according to the Institute for Clinical and Economic Review

An independent non-profit organisation that evaluates clinical and cost effectiveness of new medicines has found the price of GlaxoSmithKline’s drug for severe asthma should be as much as 76% lower to justify its value, according to the group’s latest draft report.

The Institute for Clinical and Economic Review, which is based in Boston, said its analysis indicated that Glaxo’s Nucala should be priced at $7,800 (€7,175) to about $12,000 a year.

That’s far below the drug’s list price of $32,500 a year.